ALS TDI collaborates with leaders in both academia and industry to accelerate
ALS therapeutic development, including Biogen Idec, UCB, Aestus Therapeutics, MDA and RGK Foundation.
«We are thrilled about the potential this collaboration holds to accelerate
ALS therapeutic development,» said Steve Perrin, PhD, CEO and Chief Scientific Officer at ALS TDI.
Not exact matches
Previous studies in
development of various
therapeutic approaches for
ALS typically used pre-symptomatic mice.